• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·4512.T
Share

Wakamoto Pharmaceutical Co.,Ltd. Stocks

¥ 270Last Updated 22.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

¥ 59.22M

¥ 270
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 01:35

Revenue from Google's cloud business jumped 82%. The growth rate once again surprised the market.

23.07.2026 01:21

Tesla's earnings came in one and a half times lower than expected. Its stock price fell

23.07.2026 00:47

Europe may not be able to secure the necessary volume of LNG in time for winter: gas prices have risen by 50%

23.07.2026 00:23

Yields on 30-year U.S. Treasury bonds have remained near their highest levels for the longest period since 2007

22.07.2026 23:30

Airbus shares have soared. It may challenge Boeing in the battle for the largest airliners

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026